TARGET Surveillance, a part of the LIBRA initiative: susceptibility of Enterobacter spp. and Klebsiella spp. isolated during 2003
Abstract number: 1134_04_214
Morrissey I., Colclough A., McKeon M., Dowling K., Viljoen L., Veltman T.
To assess the antibiotic (ABX) susceptibility of Enterobacter (E). sp and Klebsiella (K). sp circulating in France, Germany, Italy, Mexico, South Africa, Spain and the USA during 2003.
MICs for ampicillin (AMP), amoxycillin/clavulanate (AMX/C), ceftazidime (CTZ), ceftriaxone (CTX), ciprofloxacin (CIP), gentamicin (GEN), imipenem (IMI), nitrofurantoin (NIT), piperacillin (PIP), piperacillin/tazobactam (PIP/TAZ) and Trimethoprim/sulphamethoxazole (TM/SX) were determined by microbroth dilution.
Percent ABX susceptibility (sus) of all K. sp and E. sp collected are shown in the Table (N, number of isolates collected). Against both pathogens, IMI and GEN were the most active parenteral agents and CIP the most active orally available ABX. For E. sp, lower sus was observed in Italy and Mexico: CTZ or CTX (5060%), GEN (7080%), PIP (~50%) or PIP/TAZ (~60%). TM/SX sus was also low in Mexico (~60%) and CIP slightly lower in Italy (82.2%). Lower sus to CTZ or CTX (~60%), CIP (71.6%), PIP (60.3%), PIP/TAZ (67.8%) or TM/SX (82.9%) was seen in France. Interestingly, NIT sus was low in France and Germany (1320%) but higher in Mexico or Spain (~50%). Higher E. sp sus was observed in Germany (except NIT), Spain or the USA, with (90% sus to CIP, GEN, IMI or TM/SX. Higher CIP sus also occurred in South Africa ((95%). Generally K. sp sus was lower in Mexico and South Africa but isolates were still over 90% sus to IMI or CIP. Higher K. sp sus was observed in Spain and the USA ((90% for all ABX except AMP or PIP). However, K. sp showed low AMP or NIT sus worldwide.
K. sp is generally more sus to ABX than E. sp. Of the ABX included within the study only CIP, GEN or IMI showed consistent activity against E. sp within each country investigated. Of these CIP would be the most suitable for step-down and/or community use against E. sp or K. sp infection.
|Session name:||XXIst ISTH Congress|
|Back to top|